MediChem Life Sciences Enters into Structural Proteomics Agreement With Cephalon
CHICAGO, Oct. 24 /PRNewswire/ -- MediChem Life Sciences (Nasdaq: MCLS - news), a drug discovery company, announced today that it has signed a service agreement for protein crystallography of an undisclosed target with Cephalon, Inc., an international biopharmaceutical company headquartered in West Chester, PA.
Scientists at MediChem's Emerald BioStructures subsidiary will obtain quantities of the purified target and several proprietary small molecule ligands from Cephalon. MediChem will then screen thousands of conditions to co-crystallize the two together.
When the co-crystallizations are complete, MediChem will utilize Argonne National Laboratory's Advanced Photon Source (APS) to collect the data necessary to solve the structures of the complexes at near-atomic resolution. This will provide Cephalon researchers with detailed three-dimensional pictures of the small molecule compounds bound to the target.
In consideration for work outlined in the service agreement, MediChem will receive technology access fees, FTE funding, payments upon completion of specified milestone events, and retain rights to technology, data and improvements related to its structural proteomics platform.
``The technology access fees that we receive give Cephalon access to our high-throughput, automated crystallization technologies, resulting in more rapid access to biophysical data,'' said Michael T. Flavin, Ph.D., president and CEO of MediChem... |
